ClinVar Miner

Submissions for variant NM_001378452.1(ITPR1):c.800C>T (p.Thr267Met)

dbSNP: rs797044955
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000190812 SCV000244253 pathogenic Inborn genetic diseases 2013-06-27 criteria provided, single submitter clinical testing
Schule lab, Hertie Institute for Clinical Brain Research RCV000677366 SCV000700188 pathogenic Spinocerebellar ataxia type 29 2018-02-09 criteria provided, single submitter research
Baylor Genetics RCV000677366 SCV000807309 uncertain significance Spinocerebellar ataxia type 29 2017-09-01 criteria provided, single submitter clinical testing Likely pathogenicity based on finding it once in our laboratory de novo in a 12-year-old female with cerebellar ataxia with tremor (onset in first year of life), significant motor delays, moderate speech delays, hypoplastic cerebellar vermis
GeneDx RCV001552791 SCV001773550 pathogenic not provided 2022-01-12 criteria provided, single submitter clinical testing Published functional studies suggest ITPR1 loss-of-function (Synofzik et al., 2018); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31632679, 25794864, 24091540, 29925855, 29878067, 28659154, 30842224, 32290556, 30301590, 32695065, 33163565, 27535533)
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center RCV001552791 SCV002051641 pathogenic not provided 2021-01-06 criteria provided, single submitter clinical testing PS2, PS3, PS4
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein RCV000677366 SCV002512364 pathogenic Spinocerebellar ataxia type 29 2022-01-23 criteria provided, single submitter clinical testing ACMG classification criteria: PS3 supporting, PS4 strong, PM2 moderate, PM6 moderate, PP3 supporting
MGZ Medical Genetics Center RCV000677366 SCV002581407 pathogenic Spinocerebellar ataxia type 29 2021-11-05 criteria provided, single submitter clinical testing
Invitae RCV001552791 SCV003525035 pathogenic not provided 2023-02-14 criteria provided, single submitter clinical testing This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 267 of the ITPR1 protein (p.Thr267Met). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with autosomal dominant spinocerebellar ataxia (PMID: 24091540, 31632679). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 208786). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ITPR1 protein function. For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics RCV003152595 SCV003841225 pathogenic Spinocerebellar ataxia type 15/16 criteria provided, single submitter clinical testing
Genome Medicine, Institute for Basic Research in Developmental Disabilities RCV000677366 SCV003929451 pathogenic Spinocerebellar ataxia type 29 criteria provided, single submitter clinical testing The variant is classified as “Pathogenic” as per the American College of Medical Genetics (ACMG) guidelines (Richards et al. 2015). Two “Strong” criteria (PS1, PS3) are met as the variant has been previously reported to be pathogenic and there is functional evidence to support a damaging effect on intracellular calcium modulation (Ngo et al. 2019; Ohba et al. 2013; Sasaki et al. 2015; Synofzik et al. 2018; Zambonin et al. 2017; Iwama et al. 2019; Kashimada et al. 2019; Won et al. 2020; Gauquelin et al. 2020; Martínez-Rubio et al. 2022; Romaniello et al. 2022; Zhi et al. 2023). Additionally, the variant meets “Moderate” criteria PM2, given that the variant is not present in GnomAD (Chen et al. 2022). “Supporting” criteria PP3 is also met. The Phred-scaled Combined Annotation Dependent Depletion (CADD) score was calculated to be greater 26.2, which suggests that the pathogenicity of the variant is in the 99.8 percentile (Rentzsch et al. 2019). The Sorting Intolerant From Tolerant (SIFT) and PolyPhen scores also support the variant’s pathogenicity and were calculated to be 0 and 0.994 respectively (Ng and Henikoff 2003; Adzhubei, Jordan, and Sunyaev 2013).
Institute of Human Genetics, Clinical Exome/Genome Diagnostics Group, University Hospital Bonn RCV000677366 SCV004032470 pathogenic Spinocerebellar ataxia type 29 2023-05-24 criteria provided, single submitter clinical testing
Department of Rehabilitation Medicine, Chungnam National University Hospital RCV000677366 SCV004036077 pathogenic Spinocerebellar ataxia type 29 2022-09-26 no assertion criteria provided clinical testing Mutations in the c.800C>T (p.Thr267Met) locus have been documented in the literature for associations with the diagnosis of spinocerebellar ataxia 29. Threonine at position 267 is located at the IRBIT binding region and IP3 binding domain. Variants in the ITPR1 gene have caused loss of function of the IP3R1 protein, thus disrupting calcium release from the endoplasmic reticulum of cells, especially Purkinje cells of the cerebellum, thus causing cerebellar degeneration and characteristics of SCA29.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.